New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSemaglutide vs ARA-290

Semaglutide vs ARA-290

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Semaglutide
Immune SupportRecovery & Repair
ARA-290
Summary
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Half-Life
~7 days
~2–4 hours (SC administration)
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
4 mg (fixed dose)
Frequency
Once weekly, subcutaneous
Once daily
Key Benefits
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
Side Effects
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
Stacks With